Amgen sharpens focus on genetic sequencing with $66M investment
Reinforcing its ability to identify and validate disease targets, Amgen $AMGN on Thursday said it would fork out £50 million ($66 million) to buy shares in privately-held Oxford Nanopore Technologies, which has developed the first portable DNA/RNA sequencer and has so far raised nearly half a billion pounds in funding.
The new investment builds on Amgen’s acquisition of deCODE Genetics back in 2012 for $415 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.